Regeneron Pharmaceuticals
Yahoo Finance • 10 hours ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both d... Full story
Yahoo Finance • 2 days ago
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – REGN
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit se... Full story
Yahoo Finance • 2 days ago
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman
SAN FRANCISCO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal challenges, and analyst downgrades. TD Cowen rece... Full story
Yahoo Finance • 3 days ago
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherw... Full story
Yahoo Finance • 3 days ago
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both d... Full story
Yahoo Finance • 3 days ago
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc... Full story
Yahoo Finance • 3 days ago
Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) should contact The Gross Law Firm about pending Class Action - REGN
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are e... Full story
Yahoo Finance • 5 days ago
DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story
Yahoo Finance • 5 days ago
DEADLINE ALERT for NXT, RVNC, REGN, BIOA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
BENSALEM, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story
Yahoo Finance • 5 days ago
REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities... Full story
Yahoo Finance • 5 days ago
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – REGN
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit se... Full story
Yahoo Finance • 6 days ago
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision expected by June 20, 2025Priority revi... Full story
Yahoo Finance • 6 days ago
Communiqué de presse : La FDA accorde un examen prioritaire à la demande de licence supplémentaire relative au Dupixent pour le traitement ciblé de la pemphigoïde bulleuse
La FDA accorde un examen prioritaire à la demande de licence supplémentaire relative au Dupixent pour le traitement ciblé de la pemphigoïde bulleuse Si la demande est approuvée, le Dupixent sera le premier et le seul médicament ciblé pour... Full story
Yahoo Finance • 6 days ago
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrating significant improvements in sustai... Full story
Yahoo Finance • 6 days ago
ROSEN, A GLOBALLY RESPECTED LAW FIRM , Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both d... Full story
Yahoo Finance • 6 days ago
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens Berman
SAN FRANCISCO, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing legal challenges, analysts TD Cowen recentl... Full story
Yahoo Finance • 9 days ago
Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing legal challenges, analysts TD Cowen recentl... Full story
Yahoo Finance • 10 days ago
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both d... Full story
Yahoo Finance • 10 days ago
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit se... Full story
Yahoo Finance • 11 days ago
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are e... Full story
